Trials / Completed
CompletedNCT02087943
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 191 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Orally twice a day (BID) |
| DRUG | Apremilast | Orally twice a day (BID) |
| DRUG | Placebo | Orally twice a day (BID) |
| DRUG | Placebo | Orally twice a day (BID) |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-10-01
- Completion
- 2016-02-01
- First posted
- 2014-03-14
- Last updated
- 2020-05-07
- Results posted
- 2016-12-12
Locations
31 sites across 3 countries: United States, Canada, Japan
Source: ClinicalTrials.gov record NCT02087943. Inclusion in this directory is not an endorsement.